Optimization of Nanovaccines and Immunosuppressants... A New Chapter in Cancer Treatment

[Asia Economy Reporter Junho Hwang] Domestic researchers have developed a new anticancer nano vaccine and a technology to optimize immunotherapy using it. The research team evaluated this as a step closer to conquering cancer.

On the 16th, the research team led by Professor Sangyong Jeon of the Department of Biological Sciences at the Korea Advanced Institute of Science and Technology (KAIST) announced the successful development of a nanoparticle vaccine for effective anticancer immunotherapy. The team developed a nanoparticle-based anticancer vaccine capable of simultaneous delivery of tumor peptide antigens, which are amino acid polymers that induce immune responses, and immune adjuvants. Through this, they achieved a T cell (immune cell)-based specific immune response (a highly advanced defense system different from innate immunity) involving lymphocytes responsible for cellular immunity.

In particular, the researchers enhanced therapeutic effects by adjusting the administration order and timing of the newly developed nanoparticle-based anticancer vaccine and existing anticancer immune tolerance inhibitors.

Professor Sangyong Jeon said, "We developed a nanoparticle vaccine aimed at effective anticancer immunotherapy. Along with this, we developed a new combination therapy strategy that can overcome the limitations of existing anticancer vaccines and immune tolerance inhibitors. Through this, we expect to apply it to various anticancer immunotherapies in the future to further enhance therapeutic efficacy."

Meanwhile, the results of this study were published in the international chemistry journal Angewandte Chemie.

This content was produced with the assistance of AI translation services.